Since prohibitin and ANX2 were identified as surface markers of AdECs useful for its targeting with a peptide precision therapy [98,99], accumulating evidence suggests that the potential of prohibitin or ANX2 as a therapeutic agent against obesity. This evidence concerns the gene PHB1 and obesity due to melanocortin 4 receptor deficiency.